According to Gram Research analysis, activating a protein called Akt1 inside kidney cells reversed kidney damage and improved blood sugar control in mice with type 2 diabetes. In a study published in The Journal of Endocrinology, mice with activated mitochondrial Akt1 showed marked reductions in protein leakage, kidney scarring, and blood waste levels, while also producing more insulin and maintaining lower blood glucose. This discovery suggests a novel treatment approach for diabetic kidney disease, though human studies are still needed.
Scientists discovered that a protein called Akt1 inside kidney cell power plants plays a crucial role in protecting kidneys from diabetes damage. Using specially designed mice, researchers found that activating this protein reversed kidney disease caused by a high-fat, high-sugar diet. The same activation also improved how the body handles blood sugar and insulin production. This finding suggests a completely new way to treat diabetic kidney disease, one of the leading causes of kidney failure worldwide. The research reveals an unexpected connection between kidney health and the pancreas’s ability to control blood sugar.
Key Statistics
A 2026 research study in The Journal of Endocrinology found that activating mitochondrial Akt1 in kidney cells of diabetic mice significantly reduced urinary albumin leakage, fasting blood urea nitrogen levels, and kidney fibrosis compared to untreated diabetic controls.
Mice with activated renal tubular mitochondrial Akt1 showed improved glucose tolerance and higher insulin secretion levels, with increased pancreatic beta cell mass, revealing previously unknown communication between kidney and pancreatic function in glucose metabolism.
The study demonstrated that levels of kidney-scarring proteins α-smooth muscle actin and transforming growth factor-β1 were markedly reduced in mice with activated mitochondrial Akt1, indicating reversal of diabetic kidney disease progression.
The Quick Take
- What they studied: Whether activating a specific protein (Akt1) inside kidney cells could prevent or reverse kidney damage caused by type 2 diabetes
- Who participated: Genetically modified mice that developed type 2 diabetes from eating a high-fat, high-sugar diet for 40 weeks. Some mice had the ability to activate the Akt1 protein when given a specific drug
- Key finding: Mice with activated kidney cell Akt1 showed major improvements in kidney function and structure, lower blood sugar levels, and better insulin production compared to mice without this activation
- What it means for you: This research suggests a potential new treatment approach for diabetic kidney disease, though human studies are still needed. If confirmed in people, it could offer hope to millions with diabetes-related kidney problems
The Research Details
Researchers created special laboratory mice with a unique ability: they could turn on a protein called Akt1 inside their kidney cells whenever scientists gave them a drug called Tamoxifen. This allowed scientists to study exactly what happens when this protein is activated. The mice were fed a diet high in fat and sugar for 40 weeks to develop type 2 diabetes, mimicking how the disease develops in humans. Half the mice received Tamoxifen to activate the Akt1 protein, while the other half did not. Scientists then compared kidney health, kidney function, and blood sugar control between the two groups.
This approach is powerful because it lets researchers isolate the effect of one specific protein change without affecting other body systems. The 40-week diet period allowed enough time for kidney damage to develop, making it possible to see whether activating Akt1 could reverse that damage. Scientists measured multiple markers of kidney health, including protein leakage in urine, blood waste levels, and microscopic changes in kidney tissue structure.
The study also examined how this kidney protein affected the pancreas and blood sugar control. Researchers used specialized tests including glucose tolerance tests and insulin stimulation studies to understand the full impact of activating this protein.
Using genetically modified mice allows scientists to test whether a specific protein change can treat disease without the risks of testing new treatments directly in humans. This type of research is essential for identifying promising new treatment targets before moving to human clinical trials. The 40-week timeline is long enough to develop realistic disease similar to what happens in people
This is original research published in a peer-reviewed scientific journal, meaning other experts reviewed the methods and findings. The use of a controlled animal model allows for precise measurement of effects. However, results in mice don’t always translate to humans, so human studies would be needed to confirm these findings. The study appears well-designed with appropriate control groups and multiple measurements of kidney and metabolic function
What the Results Show
Mice with activated mitochondrial Akt1 showed dramatic improvements in kidney health. Protein leakage in urine, a key sign of kidney damage, was markedly reduced. Blood waste levels (BUN) were significantly lower, indicating better kidney filtering function. Under the microscope, kidney tissue showed much less scarring and damage compared to control mice. Importantly, these improvements occurred even though all mice had been fed the diabetes-inducing diet.
The protein markers of kidney damage were also substantially reduced. Two key proteins that signal kidney scarring, α-smooth muscle actin and transforming growth factor-β1, were significantly lower in the treated mice. This suggests the kidney tissue was actually healing and not progressing toward permanent damage.
Beyond kidney protection, the activated Akt1 protein improved blood sugar control. Mice with activated Akt1 had lower fasting blood glucose levels and showed better glucose tolerance when given a glucose challenge. Their pancreases produced more insulin, and they had more insulin-producing beta cells. These improvements suggest the protein influences how the whole body manages blood sugar, not just kidney health.
The research revealed an unexpected connection between kidney cells and pancreatic insulin production. When kidney cell Akt1 was activated, the pancreas responded by making more insulin and producing more insulin-producing cells. This suggests the kidneys and pancreas communicate in ways scientists didn’t fully understand before. The study also showed that insulin secretion improved both at baseline and when stimulated by glucose, indicating more robust pancreatic function overall
Previous research suggested that mitochondrial dysfunction, damage to the power plants inside cells, contributes to diabetic kidney disease. This study builds on that knowledge by showing that specifically restoring Akt1 function in kidney cell mitochondria can reverse kidney damage. The discovery of metabolic crosstalk between kidney and pancreatic function is novel and suggests previous research may have missed important connections between kidney health and blood sugar control
This research was conducted in mice, not humans, so results may not directly apply to people with diabetes. The study used genetically modified mice with artificially activated Akt1, which is different from developing a drug that could activate this protein in human patients. The sample size of mice is not specified in the abstract. The study examined only type 2 diabetes induced by diet; results might differ in other forms of diabetes or kidney disease. Long-term safety of Akt1 activation in humans is unknown
The Bottom Line
This research is promising but preliminary. It suggests that activating mitochondrial Akt1 in kidney cells could be a new treatment strategy for diabetic kidney disease. However, human clinical trials are needed before any new treatment could be recommended. Current diabetes and kidney disease management should continue as prescribed by healthcare providers. This research may eventually lead to new medications, but that is likely years away
People with type 2 diabetes, especially those at risk for kidney disease, should be aware of this research direction. Healthcare providers treating diabetic kidney disease should monitor for future human studies. Researchers in diabetes and kidney disease fields will find this work particularly relevant. People with early signs of kidney damage from diabetes may eventually benefit from treatments based on this research
This is early-stage research. If promising human trials begin soon, it could take 5-10 years or more before a new treatment based on this discovery becomes available to patients. In the meantime, current treatments for diabetes and kidney disease remain the standard of care
Frequently Asked Questions
Can activating Akt1 in kidney cells reverse kidney damage from diabetes?
In mice, activating mitochondrial Akt1 in kidney cells reversed kidney damage from type 2 diabetes, reducing protein leakage and scarring. However, this has only been tested in laboratory mice, not yet in humans. Human clinical trials would be needed to confirm whether this approach works in people.
How does kidney cell Akt1 affect blood sugar control?
The research revealed that activating Akt1 in kidney cells improves pancreatic insulin production and blood glucose control. This suggests kidneys and pancreas communicate through a previously unknown pathway. Mice with activated Akt1 had lower fasting blood glucose and better glucose tolerance.
When will a treatment based on this kidney protein discovery be available?
This is early-stage research in mice. Developing a human treatment would require years of additional research, including clinical trials. If development proceeds quickly, a potential treatment might become available in 5-10 years or longer. Current diabetes medications remain the standard of care.
Does this research apply to type 1 diabetes or only type 2?
This study specifically examined type 2 diabetes induced by a high-fat, high-sugar diet in mice. Results may differ for type 1 diabetes or other kidney diseases. Additional research would be needed to determine if Akt1 activation helps other forms of diabetes or kidney disease.
What should people with diabetic kidney disease do based on this research?
Continue current diabetes and kidney disease treatments as prescribed by your healthcare provider. Monitor kidney function through regular lab work. Maintain healthy diet and exercise habits. Stay informed about future clinical trials, as this research may eventually lead to new treatment options for diabetic kidney disease.
Want to Apply This Research?
- Users with diabetes should track fasting blood glucose levels weekly and record any changes in urine protein (if tested by healthcare provider). Monitor kidney function markers (creatinine, BUN) through regular lab work ordered by their doctor, noting trends over months
- While waiting for potential future treatments, users can optimize current diabetes management by logging daily diet quality, exercise minutes, and weight. Focus on reducing high-fat, high-sugar foods similar to those used in the study to induce diabetes in mice
- Set up quarterly reminders to review kidney function test results with healthcare provider. Track blood sugar patterns to identify improvements from current lifestyle and medication changes. Create a health timeline showing kidney function trends over 6-12 months to share with doctors
This article summarizes research findings from a mouse study and should not be interpreted as medical advice. Diabetic kidney disease is a serious condition requiring professional medical care. Do not change diabetes or kidney disease medications or treatments based on this research. Consult your healthcare provider about your individual risk for kidney disease and appropriate screening. This research is preliminary and has not yet been tested in humans. Any future treatments based on this work would require extensive human clinical trials and regulatory approval before becoming available to patients.
This research translation is published by Gram Research, the science division of Gram, an AI-powered nutrition tracking app.
